A Study to Learn About the Study Medicine (Called ARV-471) in People With ER+/HER2- Advanced BC in China

Breast Cancer Clinical Trial

Official title:

A PHASE 1, OPEN LABEL STUDY EVALUATING THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ARV-471 (PF-07850327) AS A SINGLE AGENT IN CHINESE PARTICIPANTS WITH ER+/HER2- ADVANCED BREAST CANCER

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05732428
• Other study ID #: C4891018
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: February 20, 2023
• Est. completion date: November 7, 2024

Study information

• Verified date: April 2024
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this clinical trial is to learn about the pharmacokinetics. safety and tolerability of the study medicine (called ARV-471) for the potential treatment of advanced estrogen receptor postive and human epidermal growth factor receptor 2 negative breast cancer.

This study is seeking participants have

• ER+/HER2- advanced breast cancer

• received at least 1 line of endocrine therapy with or without CDK4/6 inhibitor

• received up to 2 prior regimens of chemotherapy for advanced setting. All participants in this study will receive ARV-471. ARV-471 will be given by mouth at home once a day. The experiences of people receiving the study medicine will be examined. This will help determine if the study medicine is safe and effective.

Participants will take part in this study until their cancer is no longer responding. During this time, they will have visits at the study clinic about every 4 weeks.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 9
• Est. completion date: November 7, 2024
• Est. primary completion date: March 29, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histological or cytological diagnosis of breast cancer with evidence of ER+/HER2- locally advanced or metastatic disease, which is not amenable to surgical resection or radiation therapy with curative intent.

• Received at least 1 line of SOC of endocrine therapy with or without CDK4/6 inhibitor for locally advanced or metastatic disease.

• Up to 2 prior regimens of chemotherapy for advanced or metastatic disease setting are allowed.

Exclusion Criteria:

• Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or progressive growth. Participants with a history of CNS metastases or cord compression are eligible if they have been definitively treated (eg, radiotherapy, stereotactic surgery) and clinically stable (including patients with residual CNS symptoms/deficits) off enzyme-inducing anticonvulsants and steroids for at least 28 days prior to first dose of study drug.

• Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (New York Heart Association Class III or IV), cerebrovascular accident, transient ischemic attack, or symptomatic pulmonary embolism or other clinically significant episode of thromboembolic disease, congenital long QT syndrome, Torsade de Pointes, serious conduction system abnormalities (eg, bifascicular block defined as right bundle branch and left anterior or posterior hemiblock, 3rd degree AV block), clinically important arrhythmias, left anterior hemiblock (bifascicular block), ongoing cardiac dysrhythmias of NCI CTCAE Grade =2, atrial fibrillation of any grade.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• ARV-471
ARV-471 will be administered orally once daily with food (eg, a light meal of approximately 400 to 600 calories which includes a mixture of fat carbohydrates, and protein) at RP3D for monotherapy defined in study ARV-471-mBC-101, in continuous dosing over 28-day cycles

Locations

Country	Name	City	State
China	Cancer Hospital Chinese Academy of Medical Science	Beijing	Beijing
China	Jilin Cancer Hospital	Changchun	Jilin
China	Sir Run Run Shaw Hospital of Zhejiang University School of Medicine	Hangzhou	Zhejiang
China	Cancer Hospital Chinese Academy of Medical Sciences	Shanghai
China	The First Affiliated Hospital of Xi'an Jiaotong University	Xi'an	Shaanxi

Sponsors (2)

Lead Sponsor	Collaborator
Pfizer	Arvinas Estrogen Receptor, Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Single dose Cmax (Maximum plasma concentration)	Maximum plasma concentration	0, 1, 2, 4, 6, 8, 12, 24 hours post-dose up to Day 2
Primary	Single dose AUCtau	Area under the concentration-time profile from time zero to time tau (t), the dosing interval, where tau = 24 hours (QD dosing)	0, 1, 2, 4, 6, 8, 12, 24 hours post-dose Up to Day 2
Primary	Multiple dose Cmax	Maximum Observed Plasma Concentration (Cmax)	0, 1, 2, 4, 6, 8, 12, 24 hours post-dose Up to Day 71
Primary	Multiple dose AUCtau	Area under the concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 24 hours.	0, 1, 2, 4, 6, 8, 12, 24 hours post-dose Up to Day 71
Secondary	Objective Response Rate - Percentage of Participants With Objective Response	Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response.; Per RECIST v1.1: CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis <10 mm). No new lesions. PR was defined as >=30% decrease under baseline of Percentage of participants with objective response based assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST).	Baseline up to 24 weeks
Secondary	Percentage of Participants With Clinical Benefit	Percent of participants with confirmed complete response (CR), partial response (PR) or stable disease (SD) for at least 24 weeks on study according to RECIST.; Per RECIST v1.1: CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis <10 mm). No new lesions. PR was defined as >=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. SD was defined as not qualifying for CR, PR, Progressive Disease (PD).	Baseline up to 24 weeks
Secondary	Duration of Objective Response (DOR)	DOR: time from date of first documented response (CR or PR) to first documented progression or death due to underlying cancer. RECIST V1.1, a) CR: disappearance of all lesions; any pathological lymph nodes (TLs) or non-pathological (non-TLs) must have reduction in short axis to <10 mm; normalization of tumor marker level for non-TLs; b) PR: >=30% decrease in sum of diameter (dia) of all TLs, referring baseline sum of dia; c) PD: >=20% increase in sum of diameter of all measured target lesions taking as reference smallest sum of diameter of all target lesions recorded at or after baseline, sum must also be absolute increase of >=5 mm. Unequivocal progression of existing non-target lesions. Appearance of at least 1 new lesion. If a participant with a CR or PR had no PD or death due to underlying cancer, participants was censored at date of last adequate tumor assessment.	From the date of first documented response (CR or PR) until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 weeks
Secondary	Presence (rate) or absence of blood biomarkers	To identify biomarkers (ESR1 mutation) of complete response and progression if occurs	immediately after the end of treatment
Secondary	Number of Participants With Notable Electrocardiogram (ECG) Values	Criteria for notable ECG values were as follow: QT interval (in millisecond [msec]) new (newly occurring post-baseline value) greater than (>) 450, 480, 500, increase from baseline >30, increase from baseline >60; corrected QT interval by Fredericia formula (QTcF) in msec new (newly occurring post-baseline value) > 450, 480, 500, increase from baseline >30, increase from baseline >60; corrected QT interval by Bazett's formula (QTcB) in msec new (newly occurring post-baseline value) > 450, 480, 500, increase from baseline >30, increase from baseline >60; heart rate in bpm new (newly occurring post-baseline value) <60 and >100.	From baseline up to 28 days after last dose of study drug
Secondary	Number of Participants With Laboratory Abnormalities	Hemoglobin (HGB),hematocrit,erythrocytes (ery.),HDL cholesterol (chl.)<0.8*lower limit of normal(LLN);reticulocytes (ret.), ret./ery. (%)<0.5*LLN,>1.5*upper limit of normal (ULN);ery. mean corpuscular (EMC) volume,EMC HGB,EMC HGB	Baseline (Day 1) up to at least 28 days after last dose of study drug
Secondary	Number of Participants With Clinically Significant Change From Baseline in Vital Signs	Vital signs (temperature, respiratory rate, pulse, systolic and diastolic blood pressure) were obtained with participant in the seated position, after having sat calmly for at least 5 minutes. Clinical significance of vital signs was determined at the investigator's discretion.	Baseline up to 28 days after last dose of study drug
Secondary	Number of Participants With Adverse Events (AEs) by type, frequency, severity (as graded by NCI CTCAE verision 5.0), timing, seriousness and relationship to study treatment	Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to [study drug] was assessed by the investigator. Participants with multiple occurrences of an AE within a category were counted once within the category. An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per CTCAE version 4, Grade 1= mild AE; Grade 2= moderate AE; Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE.	Baseline up to 28 days after the last dose of study drug
Secondary	Single dose Tmax	Time at which Cmax occurred	0, 1, 2, 4, 6, 8, 12, 24 hours post-dose Up to Day 2
Secondary	Single dose AUClast	Area under the concentration-time profile from time zero to the time of the last quantifiable concentration (Clast)	0, 1, 2, 4, 6, 8, 12, 24 hours post-dose Up to Day 2
Secondary	Single dose MRCmax	ARV-473 to ARV-471 ratio for Cmax	0, 1, 2, 4, 6, 8, 12, 24 hours post-dose Up to Day 2
Secondary	Single dose AUCinf	Area under the concentration-time profile from time zero extrapolated to infinite time	0, 1, 2, 4, 6, 8, 12, 24 hours post-dose Up to Day 2
Secondary	Single dose CL/F	Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.	0, 1, 2, 4, 6, 8, 12, 24 hours post-dose Up to Day 2
Secondary	Single dose Vz/F	Apparent volume of distribution	0, 1, 2, 4, 6, 8, 12, 24 hours post-dose Up to Day 2
Secondary	Single dose t½	Terminal half-life	0, 1, 2, 4, 6, 8, 12, 24 hours post-dose Up to Day 2
Secondary	Multiple dose Tmax	Time to Reach Maximum Observed Plasma Concentration	0, 1, 2, 4, 6, 8, 12, 24 hours post-dose Up to Day 71
Secondary	Multiple dose Vz/F		0, 1, 2, 4, 6, 8, 12, 24 hours post-dose Up to Day 71
Secondary	Multiple dose MRCmax	ARV-473 to ARV-471 ratio for Cmax	0, 1, 2, 4, 6, 8, 12, 24 hours post-dose Up to Day 71
Secondary	Rac	Accumulation ratio based on AUC (observed)	0, 1, 2, 4, 6, 8, 12, 24 hours post-dose Up to Day 71
Secondary	t½eff	Effective half-life (t½eff) based on accumulation ratio	0, 1, 2, 4, 6, 8, 12, 24 hours post-dose Up to Day 71
Secondary	Multiple dose CL/F	Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.	0, 1, 2, 4, 6, 8, 12, 24 hours post-dose Up to Day 71
Secondary	Multiple dose t½	Terminal half-life	0, 1, 2, 4, 6, 8, 12, 24 hours post-dose Up to Day 71
Secondary	Single dose MRAUCtau		0, 1, 2, 4, 6, 8, 12, 24 hours post-dose Up to Day 2
Secondary	Multiple dose AUClast		0, 1, 2, 4, 6, 8, 12, 24 hours post-dose Up to Day 71
Secondary	Multiple dose Cmin		0, 1, 2, 4, 6, 8, 12, 24 hours post-dose Up to Day 71
Secondary	Multiple dose Ctrough		0, 1, 2, 4, 6, 8, 12, 24 hours post-dose Up to Day 71

External Links

•   To obtain contact information for a study center near you, click here.